Eli Lilly Delays Alzheimer’s Filing After U.S. Coverage Call (2)

Eli Lilly & Co. is delaying its application for approval of its experimental Alzheimer’s treatment after U.S. health officials restricted reimbursement for the class of drugs.

The request for accelerated approval now won’t be complete until after the first quarter, company executives said Thursday on an earnings call. Lilly said it would complete the filing in 2022, without specifying exactly when.

The Indianapolis-based drugmaker had said that it could see approval for the therapy, donanemab, in the second half of 2022. The announcement of the shifting timeline surprised Wall Street, and Lilly’s stock dropped as much as 3.9% as of ...